nimodipine has been researched along with Coronary Disease in 4 studies
Nimodipine: A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure.
nimodipine : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm.
Coronary Disease: An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.
| Excerpt | Relevance | Reference |
|---|---|---|
| " An increasing dosage of nimodipine is accompanied by increasing cardiovascular effects." | 2.66 | [Hemodynamic effects in high-dose infusion of nimodipine, a new calcium antagonist]. ( Boldt, J; Hempelmann, G; Kling, D; Moosdorf, R; Ratthey, K; von Bormann, B, 1986) |
| "03 mg/kg bwxh nimodipine, a dosage being used in neurosurgery, can be classified as safe." | 2.66 | [Hemodynamic changes in infusion with nimodipine]. ( Boldt, J; Görlach, G; Hempelmann, G; Kling, D; von Bormann, B, 1985) |
| "Brain damage after resuscitation from cardiac arrest is believed to be related to calcium influx in ischaemic neurons and to postischaemic calcium-dependent vasospasm." | 1.28 | Nimodipine has no beneficial effect on neurological outcome in a cardiopulmonary arrest model in the rat. ( Bogaert, MG; Buylaert, WA; Calle, PA; De Ridder, L, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (50.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Roine, RO | 1 |
| Calle, PA | 1 |
| Bogaert, MG | 1 |
| De Ridder, L | 1 |
| Buylaert, WA | 1 |
| Boldt, J | 2 |
| von Bormann, B | 2 |
| Kling, D | 2 |
| Ratthey, K | 1 |
| Moosdorf, R | 1 |
| Hempelmann, G | 2 |
| Görlach, G | 1 |
2 trials available for nimodipine and Coronary Disease
| Article | Year |
|---|---|
[Hemodynamic effects in high-dose infusion of nimodipine, a new calcium antagonist].
Topics: Coronary Artery Bypass; Coronary Disease; Dose-Response Relationship, Drug; Hemodynamics; Humans; Hy | 1986 |
[Hemodynamic changes in infusion with nimodipine].
Topics: Anesthesia, General; Calcium Channel Blockers; Coronary Artery Bypass; Coronary Disease; Dose-Respon | 1985 |
2 other studies available for nimodipine and Coronary Disease
| Article | Year |
|---|---|
Nimodipine in patients with heart disease.
Topics: Antihypertensive Agents; Calcium Channel Blockers; Cerebrovascular Disorders; Clinical Trials as Top | 1996 |
Nimodipine has no beneficial effect on neurological outcome in a cardiopulmonary arrest model in the rat.
Topics: Animals; Blood Pressure; Cell Survival; Coronary Disease; Disease Models, Animal; Electrocardiograph | 1990 |